Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

News · November 03, 2022

ANA 2022: Preventive Eptinezumab Tied to Downgrades in Migraine Diagnosis

Change in diagnostic classification for current headache diagnosis seen for 35.7 to 48 percent of eptinezumab-treated patients

PracticeUpdate Editorial Team


Further Reading